Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hair loss showdown: spray or pill? new study to find out

NCT ID NCT07273799

Disease control Sponsor: Sheikh Zayed Federal Postgraduate Medical Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two forms of minoxidil—a topical spray and an oral pill—for treating androgenetic alopecia (common hair loss) in 200 men and women aged 18 to 50. Over 6 months, researchers will measure hair regrowth, shedding, and side effects. Participants will use either the spray or the pill, along with a placebo of the other form, to see which works better and is safer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
minoxidil
What this could lead to
If this trial succeeds, it could show that oral minoxidil is a safe and effective alternative to the topical spray for treating hair loss.
What could go wrong
This is a Phase 3 trial, but it is not yet recruiting and only includes 200 people. Oral minoxidil may cause more side effects like dizziness or unwanted hair growth, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with androgenic alopecia Norwood-Hamilton class 2-6 in males and Sinclair class 2-5 in females * History of androgentic alopecia for at least 1 year * 18 to 50 years of age * Willing to provide informed consent * Willing to not use any other hair loss treatment during the treatment period Exclusion Criteria: * History of cardiovascular disease * Use of some other hair restoration therapy in the past 6 months such as minoxidil, finasteride or PRP * Presence of other causes of alopecia (e.g., alopecia areata, scarring alopecia). * Pregnant and lactating females * Previous Hair Transplantation * Patients with a known hypersensitivity to the study drug or class of study drug * Patients with co-morbid conditions like chronic liver disease, chronic kidney disease, neurological or psychiatric disorders * Presence of any other autoimmune disease (especially thyroid disease)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenic alopecia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.